Carbamazepine, 98%

Name: Carbamazepine, 98%
SKU: FSA344360010

Carbamazepine (Carbamazepen), CAS # 298-46-4, is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker.

Change view

Quantity:

1 g

5 g

25 g

Packaging:

Glass bottle

Catalog number FSA344360010

View Price:

Quantity:

1 g

Packaging:

Glass bottle

Request bulk or custom format

Chemical Identifiers

CAS6556-16-7

IUPAC Namemanganese(2+) dihydrate oxalate

Molecular FormulaC2H4MnO6

InChI KeyHDJUVFZHZGPHCQ-UHFFFAOYSA-L

SMILESO.O.[Mn++].[O-]C(=O)C([O-])=O

Specifications

Specification Sheet

FormCrystals or powder or crystalline powder

Assay from Suppliers CofAManganese, Mn: ≥30%

Appearance (Color)White to pale pink

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

Carbamazepine is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker
It is a tricyclic antidepressant-like drug that reduces post-tetanic potentiation

Applications

Carbamazepine can be used as a sodium channel blocker and as a glutamate-transporter agonist to reduce neural activity and produce inhibitory effects in the brain
Carbamazepine is useful in the research of pain, epilepsy, and manic depression

RUO – Research Use Only

General References:

Ben-Menachem, E.; Grebe, H.P.; Terada, K.; Jensen, L.; Li, T.; De Backer, M.; Steiniger-Brach, B.; Gasalla, T.; Brock, M.; Biton, V. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia. 2019, 60(12), 2437-2447. Erratum in: Epilepsia. 2021, 62(4), 1039.
Schmitz, B.; Dimova, S.; Zhang, Y.; Chellun, D.; De Backer, M.; Gasalla, T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Res. 2020, 159, 106220.